News

Cancer Care for Older People: Evidence, Tools, and Practical Approaches

Older adults make up the largest group of people diagnosed with cancer, yet their needs are often underrepresented in clinical trials and care models. Given that the mean age of lung cancer diagnosis in Australia is 72, many lung cancer patients are older and have distinct, often complex needs, making the tailoring of cancer care to this population not just good practice—it’s a medical necessity.  

Why Geriatric Oncology matters

The cornerstone of Geriatric Oncology, a multidisciplinary field focused on the intersection of ageing, cancer, and health, designed to deliver person-centred care. 

A person’s age in years is not a reliable indicator of health. Age in numbers (their chronological age) may not compare well with how their body functions (their biological or functional age), or their capacity for certain treatments. Furthermore, a patient’s preferences may change depending on their life circumstances and their experience with cancer.

Person-centred care must acknowledge this complexity, which goes beyond clinical fitness—it encompasses logistical and functional barriers: perhaps a patient with mobility issues requires more time in a radiotherapy appointment, issues with hearing are affecting communication, or arthritis is preventing someone from being able to access supportive care medicines. To properly capture these dynamic factors and non-medical challenges, it is essential to undertake appropriate assessments and have open conversations throughout the patient’s cancer experience.

Key tools for Healthcare Professionals assessing older Adults 

A meta-analysis has shown comprehensive geriatric assessment was associated with a lower risk of treatment toxicity, indicating its potential to optimise cancer treatment in older population with cancer. It may also lead to reduced treatment toxicity, increased treatment completion, and improved health-related quality of life scores. The tools listed below can be used to assess the capacity of older Adults with cancer and assist with personalised care – matching treatment intensity to an older person’s health and values, rather than applying a one-size-fits-all approach.  

Tool Category
Tool Name
Purpose
Link
Screening
Geriatric 8 (G8)
A quick, eight-question screening tool (based on the mini nutritional assessment). A score of ≤14 triggers a formal geriatric assessment.
mdCalc
Formal Assessment
Practical Geriatric Assessment (PGA)
A pragmatic, multi-dimensional tool, recommended by ASCO guidelines for all patients ≥65 being considered for cancer treatment.
ASCO
Formal Assessment
eGFA (Electronic Geriatric Assessment)
A multidimensional assessment covering cognitive function, mobility, and vital status.
SIOG
Frailty Measurement
Clinical Frailty Scale
A nine-category, holistic scale using features like slowing down and need for help with activities of daily living (ADLs).
Rockwood
Frailty Measurement
Fried Phenotype
Based on five criteria, with three or more criteria indicating frailty: slowness, weakness, weight loss, exhaustion, and low physical activity.
Frailty Science

Development of an Optimal Care Pathway for older people with cancer 

Professor Meera Agar and A/Professor Christopher Steer with support from the COSA Geriatric Oncology Group Executive, have developed an Optimal Care Pathway (OCP) for older people with cancer. 

The new OCP maps the cancer journey for older Australians, outlining key steps and decision points to guide clinicians in delivering high-quality, evidence-based, patient-centred care. By integrating geriatric oncology principles, it seeks to promote equity, collaboration, and age-friendly practice, while addressing systemic ageism in cancer care. 

Funded by Cancer Australia, this initiative aligns with the Australian Cancer Plan and prioritises improving outcomes and experiences for older adults with cancer 

What can an older Australian diagnosed with cancer do to communicate their needs? 

Sharing as much information about your health and wellbeing with your cancer team is very important to communicate your needs, but sometimes it can be hard to find the words, or appointments may feel rushed. 

This is Me was created by older adults with cancer to encourage conversations with their healthcare team about what matters most during their cancer experience. It is designed to help people share information about their health, quality of life, and personal preferences when decisions about treatment and care are being made. 

It can be used once or many times during your care, and there are no right or wrong answers. 

Providing optimal and equitable care 

Ask ‘What Matters Most”

The fundamental principle driving optimal, equitable care is a commitment to the patient’s priorities: “What really matters to you, what matters most to you?” 

For many older individuals, there may be a strong preference for Quality of Life over the absolute length of life. Probing beyond survival statistics can assist with understanding patient goals, such as maintaining independence, being able to enjoy life (e.g., travel, spending time with family), being present for an upcoming special event and addressing fears about suffering or losing cognitive function (e.g., “Am I going to be me at the end of all of this?”)

Ageism Exists

According to WHO, ageism, displayed as stereotypes (how we think), prejudice (how we feel) and discrimination (how we act) towards others or oneself based on age, is associated with earlier death (by 7.5 years). A core message in providing comprehensive care is to not make assumptions about older people and to approach every patient with open minds and open conversations. This is especially critical in lung cancer, where a patient may be experiencing deep internal distress. Anxiety and depression may be present, and with lung cancer this is often compounded by nihilism, fatalistic thinking, or the feeling that their cancer is ‘deserved’ due to current or former tobacco smoking. Clinicians must create a safe space, a world where we do not have to judge patients. 

Adapted Consultations

Successfully treating older patients requires clinic-level flexibility and a commitment to adapting standard practice. Treatments and consultations must be individually tailored to overcome practical barriers identified during the initial assessment. For instance, mobility issues may necessitate scheduling longer than standard radiotherapy appointments to allow time for transfers, positioning, and rest. Staff must be proactive in using aids and ensuring clear communication to overcome sensory issues like poor hearing. Additionally, clinicians should be aware that low literacy levels can impede adherence to complex schedules or medication instructions. Finally, in terms of systemic therapy, utilising dose reductions upfront is often a necessary and appropriate strategy to minimise toxicities and prevent downstream complications, rather than waiting for an adverse event to occur. 

As Dr. Michael Krasovitsky reminded colleagues at TOGA 2024 ASM, optimal care is not just medical care. It means ensuring patients can spend time at home, maintain cognition, and feel connected to their families and communities. 

When healthcare teams adopt a geriatric oncology lens, they: 

  • Reduce treatment toxicities. 
  • Improve physical and social functioning. 
  • Enable shared decision-making that reflects the patient’s own priorities. 

The message is clear: cancer care for older people should always begin with the question—what matters most? 

Listen to Challenging Ageism: Optimising Lung Cancer Treatment in Older Adults

To hear the full discussion with Dr Michael Krasovitsky, A/Professor Christopher Steer, Professor Shalini Vinod, and Ms. Nicole Webb, listen to the episode here: 

Lung cancer podcast Challenging Ageism: Optimising Lung Cancer Treatment in Older Adults with Dr Michael Krasovitsky, A/Professor Christopher Steer, Professor Shalini Vinod, and Ms. Nicole Webb.

Share this

Facebook
Twitter
LinkedIn
Learn what a KRAS G12C mutation means, how targeted therapies work, and how Australian clinical trials are testing new lung cancer treatments.
The PHARAOH-A trial will evaluate savolitinib plus osimertinib in MET-positive amplified or overexpressed EGFR-mutated lung cancer after progression on prior TKI and chemotherapy.
New evidence is changing the way surgeons approach early-stage lung cancer, with lung-sparing surgery becoming an option for carefully selected patients.
Everything you need to know about the Australia-wide trial using liquid biopsy to guide treatment after targeted therapy progression in advanced lung cancer
The DEFIANT trial will evaluate datopotamab deruxtecan (Dato-DXd) in EGFR exon 20 insertion NSCLC after targeted therapy and chemotherapy.
Discover the major advances from TOGA ASM 2026, including lung cancer screening, precision medicine, immunotherapy, survivorship and multidisciplinary care shaping the future of thoracic oncology.
Professor Robert Stirling OAM devoted his career to improving the lives of people with lung cancer through clinical excellence, research, education and compassionate leadership.
Their work is often invisible, but its impact isn't. Specialist Lung Cancer Nurses are quietly becoming the backbone of modern lung cancer care.
Teletrials, also known as digi trials, are when a clinician at a primary site uses telehealth (videoconference or telephone calls) to enrol, consent, treat and/or
A simple guide to what happens after a lung CT scan in the Australian National Lung Cancer Screening Program
Updates from our Inspirational Research Grant 2025 recipients on pioneering lung microbiome research and its impact on immunotherapy efficacy.
Clinicians, nurses, consumers and health service leaders came together at TOGA’s Lung Cancer Optimal Care Pathway workshop to examine why Australia continues to struggle to
Understanding the language helps patients, families and clinicians stay informed, confident and part of the conversation.
TOGA is pleased to announce the latest appoints for our Scientific Committee.
Discover how a vibrant Lunar New Year Banquet, organised by Dr. Angeline Low and Ms. Maria Chan, raised over $50,000 for vital lung cancer research.
The MRFF is holding $1B+ in unspent funds. Learn why TOGA is calling for the release of this research funding to accelerate lung cancer breakthroughs
Discover TOGA’s FY25 highlights, including the new Strategic Plan, clinical trial milestones and record membership growth across Australia and New Zealand.
The Preventative and Quality Care Working Group represents TOGA’s commitment to improving the outcomes of thoracic cancers.
TOGA’s Working Groups are evolving to better reflect where thoracic cancer research is heading: From prevention and early detection through to advanced disease and living
Learn how to turn your endorsed research concept into a clinical trial; from sponsor selection to budgeting, data, safety and protocol design.
Learn how to design an investigator-initiated clinical trial, from refining your research idea to securing TOGA endorsement and funding.
Learn why EGFR-positive lung cancer disproportionately affects Asian populations and non-smokers. Discover modern targeted therapies and symptoms to watch for.
Discover how 2025 transformed lung cancer care in Australia. Explore the impact of national screening, modern diagnostics, and new PBS treatment approvals.
Let's take a moment to celebrate the incredible guests, ground breaking discussions, and dedicated listeners that made 2025 our most successful year yet.
If you are interested in joining TOGA on a Committee, please submit your nominations by 30 January 2026
The final Scientific Meeting of 2025 was held in November. Five concepts were presented, spanning both Recurrent and Metastatic NSCLC populations and four Mesothelioma concepts.
Bispecific antibodies target two pathways at once, reshaping lung cancer treatment through dual checkpoint blockade and targeted precision.
Research advances only improve outcomes when they are accessible to patients. TOGA drives change in lung cancer care by advocating through stakeholder submissions, including PBS.......
We are excited about awarding new grants but first, we check in on progress made by our 2024 recipients....
Learn how TOGA’s ASPiRATION study led to Medicare-funded genomic testing for lung cancer and national best practice guidelines in Australia.
DYNAMALK is a significant clinical trial investigating the potential of comprehensive genomic profiling to revolutionise the treatment of ALK+ Non-Small Cell Lung Cancer (NSCLC)
Liquid biopsy is revolutionising lung cancer care by using a blood test to examine the tumour without the need for a lung biopsy.
OCEANiC will determine if patients with resected stage II to IIIA EGFR mutant NSCLC require intensification of osimertinib monotherapy with chemotherapy.
Latest results from the SHERLOCK clinical trial show promising first-line outcomes for patients with KRAS G12C-mutated lung cancer, combining sotorasib with chemotherapy and bevacizumab.
A re-cap of the Scientific Committee meeting in August 2025 and the year to date.
Celebrating TOGA's leadership transition: We honour the service of our past Board members and welcome the new Chair and Directors who will chart TOGA’s future.